NPI: 1841438454 · SANFORD, FL 32771 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 02/04/2009
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 02/04/2009 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 9,366 | $2.15M |
| 2019 | 15,955 | $3.46M |
| 2020 | 19,754 | $3.20M |
| 2021 | 7,707 | $569K |
| 2022 | 2,870 | $195K |
| 2023 | 348 | $33K |
| 2024 | 147 | $20K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 20,183 | 847 | $3.46M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 15,764 | 1,117 | $2.46M |
| J1270 | Injection, doxercalciferol, 1 mcg | 10,368 | 717 | $1.75M |
| A4657 | Syringe, with or without needle, each | 2,603 | 934 | $614K |
| J1756 | Injection, iron sucrose, 1 mg | 2,217 | 479 | $326K |
| 83540 | 907 | 620 | $176K | |
| 83550 | 906 | 619 | $176K | |
| 82728 | 889 | 601 | $173K | |
| 85048 | 708 | 488 | $147K | |
| 85041 | 707 | 488 | $146K | |
| 83970 | 434 | 292 | $80K | |
| 82108 | 270 | 186 | $54K | |
| J0604 | Cinacalcet, oral, 1 mg, (for esrd on dialysis) | 76 | 39 | $38K |
| 82607 | 48 | 28 | $11K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 37 | 15 | $9K |
| 82746 | 30 | 16 | $6K |